(Q34630124)

3 August 2017

title

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia (English)

1 reference

3 August 2017

0 references

0 references

1 reference

1 reference

Nelson Leung

5

0 references

Deborah J. Bowen

object named as

Deborah Bowen

series ordinal

7

0 references

John C. Byrd

series ordinal

9

object named as

John C Byrd

1 reference

3 August 2017

1

Tait D Shanafelt

1 reference

3 August 2017

4

Clive S Zent

1 reference

3 August 2017

10

Neil E Kay

1 reference

3 August 2017

8

Michael R Grever

1 reference

3 August 2017

3

Susan M Geyer

1 reference

3 August 2017

2

Thomas Lin

1 reference

3 August 2017

6

Brian Kabat

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

109

1 reference

3 August 2017

issue

11

1 reference

3 August 2017

page(s)

2291-2298

1 reference

Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

Deoxycoformycin in the treatment of mature B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

Chronic lymphocytic leukemia (CLL): first-line treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

The clinical and epidemiological burden of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Chronic lymphocytic leukemia: a changing natural history?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Low-dose deoxycoformycin in lymphoid malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Chronic lymphocytic leukemia in the elderly population.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Management of chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22662

7 January 2021

Identifiers

DOI

10.1002/CNCR.22662

1 reference

3 August 2017

1 reference